Compare ARGX & URI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARGX | URI |
|---|---|---|
| Founded | 2008 | 1997 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Diversified Commercial Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.6B | 52.0B |
| IPO Year | 2017 | 1997 |
| Metric | ARGX | URI |
|---|---|---|
| Price | $815.77 | $940.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 13 |
| Target Price | $979.22 | ★ $987.83 |
| AVG Volume (30 Days) | 345.7K | ★ 544.9K |
| Earning Date | 02-26-2026 | 01-28-2026 |
| Dividend Yield | N/A | ★ 0.79% |
| EPS Growth | N/A | ★ 1.51 |
| EPS | 23.27 | ★ 38.83 |
| Revenue | $3,683,281,000.00 | ★ $15,986,000,000.00 |
| Revenue This Year | $91.44 | $6.18 |
| Revenue Next Year | $36.90 | $6.05 |
| P/E Ratio | $32.12 | ★ $23.45 |
| Revenue Growth | ★ 92.98 | 6.73 |
| 52 Week Low | $510.06 | $525.91 |
| 52 Week High | $934.62 | $1,021.47 |
| Indicator | ARGX | URI |
|---|---|---|
| Relative Strength Index (RSI) | 45.80 | 65.54 |
| Support Level | $781.07 | $896.76 |
| Resistance Level | $818.78 | $955.00 |
| Average True Range (ATR) | 24.02 | 26.20 |
| MACD | 1.66 | 4.14 |
| Stochastic Oscillator | 54.26 | 89.31 |
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
United Rentals is the world's largest equipment rental company, principally operating in the US and Canada. It has 16% share in a highly fragmented market serving general industrial (49%), commercial construction (46%), and residential construction (5%). The company operates a $21 billion fleet of equipment, including aerial platforms, forklifts, excavators, trucks, power generators, and various other materials serving local and national accounts from nearly 1,600 locations in North America and 100 abroad. It has pursued a strategy of bundling specialty rental capabilities to offer its customers more advanced solutions in addition to its core equipment rental business, supporting its ambitions to become a one-stop shop for customers and enhance and maintain its margin profile.